Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.
EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END
/PRNewswire/ -- According to the Centers for Disease Control and Prevention, arthritis affects approximately one in every four Americans, or 58.5 million...
Baudax Bio, Inc. (NASDAQ: BXRX) is engaged as a pharmaceutical company, which is focused on developing innovative products for use
December S&P 500 futures (ESZ22) are trending up +0.23% this morning after three major US benchmark indices snapped a losing streak and closed higher on Thursday as market participants cheered a rise in...
ANJESO® Net Product Revenue Up 49% Year-Over-Year; Vials Sold to End-Users Up 67% Year-Over-Year Dosing Complete in the First Cohort of the Phase I...
Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, today announced the appointment of Rick Casten as Chief Financial Officer (CFO), bolstering its executive leadership...
MALVERN, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care...
MALVERN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products...
Annual Meeting to be reconvened on May 18, 2022...